RhumbLine Advisers
PRME icon

RhumbLine Advisers’s Prime Medicine PRME Stock Holding History

RhumbLine Advisers’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$359K Buy
117,552
+798
+0.7% +$2.65K ﹤0.01% 2927
2026
Q2 		$431K Buy
116,754
+2,485
+2% +$8.25K ﹤0.01% 2861
2026
Q1 		$398K Buy
114,269
+5,860
+5% +$22.3K ﹤0.01% 2748
2025
Q4 		$376K Sell
108,409
-1,378
-1% -$6.13K ﹤0.01% 2834
2025
Q3 		$608K Buy
109,787
+11,815
+12% +$48K ﹤0.01% 2562
2025
Q2 		$242K Buy
97,972
+16,072
+20% +$24.8K ﹤0.01% 3123
2025
Q1 		$163K Buy
81,900
+9,944
+14% +$25.4K ﹤0.01% 3207
2024
Q4 		$210K Buy
71,956
+1,909
+3% +$6.7K ﹤0.01% 3170
2024
Q3 		$271K Sell
70,047
-60
-0.1% -$278 ﹤0.01% 3077
2024
Q2 		$360K Buy
70,107
+17,595
+34% +$107K ﹤0.01% 2890
2024
Q1 		$368K Buy
52,512
+1,654
+3% +$12.5K ﹤0.01% 2852
2023
Q4 		$451K Sell
50,858
-101
-0.2% -$778 ﹤0.01% 2725
2023
Q3 		$486K Buy
50,959
+3,896
+8% +$50.6K ﹤0.01% 2628
2023
Q2 		$689K Buy
+47,063
New +$657K ﹤0.01% 2496

Other funds holding PRME

Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Alessandra Capital Management
Alessandra Capital Management Torrance, California $142M AUM 42.73% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

RhumbLine Advisers's PRME Position: Q3 2026 in Review

RhumbLine Advisers increased its Prime Medicine (PRME) stake by 0.68% in Q3 2026, buying an estimated $2.65K and bringing the position to 117,552 shares worth $359K. The position accounts for ﹤0.01% of the portfolio, ranked #2927.

RhumbLine Advisers first reported a position in PRME in Q2 2023 and has held it in 14 quarters since. The position peaked at $689K in Q2 2023. 76 funds tracked by Wall St. Rank hold PRME as of Q3 2026.

  • RhumbLine Advisers held 117,552 shares of Prime Medicine worth $359K as of Q3 2026.
  • RhumbLine Advisers bought 798 Prime Medicine shares in Q3 2026, an estimated $2.65K.
  • Prime Medicine made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2927 holding.
  • RhumbLine Advisers first reported a position in Prime Medicine in Q2 2023 and has held it in 14 quarters since.
  • RhumbLine Advisers's Prime Medicine position peaked at $689K in Q2 2023.
  • 76 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.